DAOA-AS1: A Potential Drug Target for Neurological Disorders (G282706)

Target Name: DAOA-AS1

NCBI ID: G282706

DAOA-AS1

Other Name(s): G30 | DAOA antisense RNA 1 | DAOA-AS | DAOAAS

DAOA-AS1: A Potential Drug Target for Neurological Disorders

DAOA-AS1 (G30) is a protein that is expressed in the brain and is known for its role in the development and progression of several neurological disorders, including Alzheimer's disease. The protein is a key component of the brain, and its levels have been linked to the severity of these disorders.

Research has shown that DAOA-AS1 plays a crucial role in the development of neurodegeneration and the progression of neuropsychiatric disorders. It has been shown to be involved in the development of neurofibrillary tangles, which are thought to contribute to the development of Alzheimer's disease.

In addition to its role in the development of neurodegeneration, DAOA-AS1 has also been shown to play a key role in the regulation of the immune system. Studies have shown that the protein helps to modulate the immune response and that its levels are closely associated with the development of multiple sclerosis.

Given the significance of DAOA-AS1 in the development and progression of neurological disorders, it is a promising target for drug development. Researchers are currently working to develop small molecules that can modulate DAOA-AS1 levels and improve the treatment outcomes for neurodegenerative disorders.

One approach that is being explored is the use of small molecules that can modulate the activity of DNA-protein hybrids, known as nucleosome. These hybrids are thought to play a key role in the regulation of DAOA-AS1 levels and are a common target for small molecules that can modulate gene expression.

Another approach that is being explored is the use of small molecules that can modulate the activity of protein-protein interactions. These interactions are thought to play a key role in the regulation of DAOA-AS1 levels and are a common target for small molecules that can modulate protein function.

While further research is needed to fully understand the role of DAOA-AS1 in the development and progression of neurological disorders, the potential of this protein as a drug target is significant. If successful, the development of drugs that can modulate DAOA-AS1 levels could lead to new and more effective treatments for a range of neurodegenerative disorders.

Protein Name: DAOA Antisense RNA 1

The "DAOA-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DAOA-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets